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Does Initial Staging or Tumor Histology Better Identify
Asymptomatic Brain Metastases in Patients with
Non–small Cell Lung Cancer?
Ann A. Shi, MD,* Subba R. Digumarthy, MD,* Jennifer S. Temel, MD,† Elkan F. Halpern, PhD,*
Landon B. Kuester,* and Suzanne L. Aquino, MD*
Background: To determine whether the distribution, staging fea-
tures, or tumor histology of non–small cell lung cancer (NSCLC)
distinguishes neurologically symptomatic from asymptomatic pa-
tients initially diagnosed with lung cancer, and to determine whether
these factors may predict the presence of brain metastasis.
Methods: We performed a retrospective review of 809 patients with
NSCLC and brain metastases who were treated in our institution
between January 1996 and March 2003. Patients who had brain
metastasis on initial staging were included. Thoracic computed
tomographic scans were reviewed for lung tumor features and
staging. Neurological computed tomographic or magnetic resonance
image scans were assessed for distribution of brain metastases.
Medical records were reviewed for comprehensive staging, tumor
histology, and neurological symptoms. Fisher’s exact test was used
to determine any differences among tumor histology, staging, and
imaging features among patients with or without neurological symp-
toms.
Results: Of the 809 patients, 181 had brain metastasis at initial
staging. Among these 181 patients, 120 (66%) presented with
neurological symptoms (group 1); 61 (34%) patients were asymp-
tomatic (group 2). Patients with adenocarcinoma and large-cell
carcinoma had greater odds of brain metastases than patients with
squamous cell carcinoma (p  0.001). There were 106 (58.6%)
patients with adenocarcinoma, 32 (17.7%) with large cell carcinoma,
and 18 (9.9%) with squamous cell carcinoma. In both groups, most
lung cancers were in the right lung with upper lobe dominance. No
significant difference in tumor histology or T stage was found
between groups, although group 2 was more likely to have a higher
N stage. Of the 181 patients with brain metastasis, 60 (33.1%) had
N0 disease, 51 (28.2%) had T1 disease, and 23 (19.2%) had no other
metastasis. There was no correlation between number/distribution of
brain metastases and tumor histology, although patients with disease
in the cerebellum or temporal lobes had a greater likelihood of
neurological symptoms (odds ratio 3.7).
Conclusion: There was no significant difference in tumor histology,
staging, or distribution between symptomatic or asymptomatic pa-
tients with NSCLC with brain metastases. The odds of brain metas-
tases were greater in those with adenocarcinoma or large-cell car-
cinoma.
KeyWords: Non–small cell lung cancer, Imaging, Brain metastasis,
Staging.
(J Thorac Oncol. 2006;1: 205–210)
Lung cancer is a leading cause of cancer death. Approxi-mately 170,000 cases of non–small cell lung cancer
(NSCLC) are diagnosed annually in the United States.1 Al-
though the initial staging of NSCLC is essential for deter-
mining treatment approach, there is no consensus regarding
whether a full examination should be routinely performed. In
particular, the necessity of preoperative screening for distant
metastases in the brain remains a controversial topic.2–18 The
most recent joint statement of the American Thoracic Society
and the European Respiratory Society2 on pretreatment eval-
uation for NSCLC advocates no preoperative imaging of the
brain in patients with NSCLC who have no symptoms or
other evidence of distant metastases.
NSCLC does not follow a set pattern to metastasize,
and occult brain metastasis may exist in the absence of
neurological symptoms.6,7,11,19 Many investigators12–18 be-
lieve the low incidence of brain metastasis in asymptomatic
patients—particularly in those with early, local disease—
renders routine screening cost-ineffective. Others argue that
detection of occult brain metastasis will avoid increased
morbidity either by allowing earlier treatment of the brain or
by avoiding futile thoracotomies.4–9
Several prospective and retrospective studies have ex-
amined the incidence of brain metastasis. The results vary
greatly depending on the modality, size of study group, tumor
histology, size and nodal disease, and inclusion of patients
with positive or negative neurological symptoms.4–11,14–17
Knowledge of factors that may identify the presence of brain
metastasis from NSCLC may help to identify a subgroup of
patients likely to benefit from central nervous system (CNS)
imaging during initial staging. We conducted a retrospective
review of patients with NSCLC with brain metastasis on
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initial staging to investigate any association between thoracic
computed tomography (CT) features of NSCLC, i.e., distri-
bution and staging features, tumor histology, and the presence
of symptomatic or asymptomatic CNS metastases.
PATIENTS AND METHODS
This study was approved by our institution’s Human
Research Committee, and patient consent was waived. We
conducted a database search of our institution’s Cancer Reg-
istry and identified 809 patients with NSCLC and brain
metastases who were treated at our institution between Jan-
uary 1996 and March 2003. These patients’ medical records,
including radiology, pathology, surgery report, clinical notes,
and discharge summaries, were reviewed.
Institutional lung cancer staging procedure during this
time interval included the acquisition of the following non-
invasive diagnostic studies: a contrast-enhanced CT of the
thorax and abdomen, magnetic resonance (MRI) or CT of the
head, bone scan, physical and neurological examination, and
blood chemistries. Invasive diagnostic procedures included
percutaneously needle biopsy of lung nodules and masses
unless a suspected metastatic site was found on imaging,
which alternatively would be biopsied for both diagnosis and
staging. Fluorodeoxyglucose positron emission tomography
(FDG-PET) scan was not a routine study during this time
period but is now routine in our institution. All surgical
candidates underwent mediastinoscopy before curative resec-
tion. The histological cells types that were considered con-
sistent with NSCLC included: adenocarcinoma, squamous
cell carcinoma, large-cell carcinoma, poorly differentiated
non–small-cell carcinoma, and non–small-cell carcinoma not
otherwise specified. When both intrathoracic and extratho-
racic pathologies were obtained but discordant, final diagno-
sis was based on intrathoracic pathology. Patients with a
concurrent secondary primary cancer were excluded from the
study.
Among the 809 patients, we selected two groups of
patients who had brain metastasis at initial staging. The first
group included 120 patients who presented with neurological
symptoms and were subsequently diagnosed with lung can-
cer. The second group included 61 patients who were neuro-
logically asymptomatic but had brain metastasis shown by
CT or MRI at initial staging. Only patients whose neurolog-
ical imaging was performed within 1 month of the diagnosis
of chest abnormality were included in the second group.
In group 1, 70 patients underwent brain biopsy, and one
patient had cerebrospinal fluid (CSF) cytology consistent
with NSCLC. In group 2, 13 patients underwent brain biopsy,
and one patient received CSF cytology. Of the 181 patients,
96 did not undergo brain biopsy. There were 95 patients in
group 1 and 55 patients in group 2 who had pathological data
from lung, pleural fluid, adrenal gland, or bone. Seven pa-
tients with non-pathologically proven lung cancer were in-
cluded, as they are clinically considered to have lung cancer.
Thoracic CT scans, radiology and pathology reports,
and surgical and clinical notes of these 181 patients were
reviewed for lung tumor features and staged according to the
International System for Staging Lung Cancer adopted by the
American Joint Committee on Cancer and the Union Inter-
nationale Contre le Cancer.20 Mediastinal lymph nodes larger
than 1 cm in short axis were considered to be pathological by
CT criteria. Non-pathologically enlarged nodes were consid-
ered metastatic if pathologically proven from surgical resec-
tion or positive by FDG-PET. Only nine patients underwent
PET. Two patients’ nodal staging was altered because of PET
findings. PET did not affect tumor staging for the other seven
patients. Eleven patients did not receive a chest CT; staging
data were derived from surgical results or plain radiograph
findings if available. There was no information regarding
tumor size for 37 patients, tumor location was unknown for
18 patients, and there was no information regarding nodal
disease for 8 patients. Limited clinical data were available for
several reasons: (1) chest CT was not performed at our
institution; (2) outside CT was not available for review and
tumor size or presence of mediastinal lymph nodes was not
mentioned in the radiology report; (3) multiple lung nodules
were present, and the primary lesion could not be determined.
Neurological CT or MRI scans were assessed for the
number and distribution of brain metastases. A significant
number of patients underwent both CT and MRI; in these
cases, the MRI scan was evaluated
The presence of non-CNS extrathoracic disease was
determined by abdominal and pelvic CT, bone scan, FDG-
PET imaging, and biopsy results. Five patients also under-
went musculoskeletal MRI for evaluation of various skeletal
metastases.
Fisher’s exact test was used to determine any differ-
ences among tumor histology, staging, and imaging features
among patients with or without neurological symptoms. His-
tological data were compared with the rates calculated from
the patients included in the Surveillance, Epidemiology, and
End Results (SEER) Program from 1975-1999.
RESULTS
We identified 120 neurologically symptomatic patients
(group 1) and 61 neurologically asymptomatic patients
(group 2) with brain metastasis at initial staging. The demo-
graphic information of the two study groups is listed in Table
1. There was no significant difference in the age and gender
(p  0.87) distribution between the two groups.
Of the 181 patients studied, 106 (58.6%) had adeno-
carcinoma, 32 (17.7%) had large-cell carcinoma, and 18
(9.9%) had squamous cell carcinoma (Table 2). Based on an
incidence of 37.3 % adenocarcinoma, 30.9 % squamous cell
carcinoma, 19.9 % small-cell lung cancer, and 11.9 % large-
cell carcinoma in the SEER lung cancer patient population
between 1975–1999,21 patients with adenocarcinoma and
TABLE 1. Gender and Age of Symptomatic (Group 1) and
Asymptomatic (Group 2) Patients with Brain Metastases
Number Men Women Mean age (yr) Age range (yr)
Total 181 90 91 61.3 35–85
Group 1 120 (66%) 59 61 61.9 35–85
Group 2 61 (34%) 31 30 60.1 41–81
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large-cell carcinoma had greater odds of brain metastases
than patients with squamous cell carcinoma (p  0.001).
There was no statistically significant difference in tumor
histology between groups 1 and 2 (p  0.56).
There was no significant difference in T stage between
the two groups (p  0.28), although group 2 was more likely
to have a higher N stage (p  0.001) (Table 3). The most
common tumor stage was T2 (38.7%), followed by T1
(28.2%), T3 (7.7%), and T4 (5%). The tumor stage was not
available for 37 of 181 patients (20.4%).
Among the patients studied, 33.2% had N0 disease,
which was the most common; 7.2%, 31.5%, and 23.7% had
N1, N2, and N3, respectively (Table 3). Nodal status could
not be determined in eight (4.4%) patients.
Of the 181 patients, 56 (30.9%) had no distant metas-
tasis other than the brain. Of these, 20 symptomatic patients
(group 1) and 3 asymptomatic patients (group 2) had no
evidence of nodal metastasis (N0) on imaging. Another 79
(43.6%) had additional non-CNS metastases. The remaining
46 patients (25%) had imaging findings suspicious for me-
tastasis, but no biopsy or follow up imaging was available for
confirmation.
Information regarding laterality (right versus left lung)
of the tumor was available for 167 patients, and the lobar
distribution was available for 173 patients. In both groups,
most lung cancers were in the right lung (61.7% overall) with
an upper and middle lobe dominance (75.7% overall) (Table
2). No significant distribution differences were found in
laterality (p  0.25) and lobar distribution (p  0.16) of the
primary tumor between symptomatic and asymptomatic pa-
tients.
Patients with squamous cell tumor and NSCLC not
otherwise specified were less likely to have CNS spread in the
absence of nodal metastases(Table 4). On the contrary, pa-
tients with large-cell tumors had greater odds of brain me-
tastasis regardless of nodal disease (p  0.01).
We reviewed head CT and MRI scans and found the
pattern of CNS involvement of NSCLC by histology was
very similar between the two groups. There were a nearly
equal number of patients with a single brain metastasis and
those with multiple brain metastases by all cell types (Table
5). Multiple metastatic foci just as frequently caused neuro-
logical symptoms as a single focus: 57 of 91 patients (62.6%)
with multiple metastases were neurologically symptomatic
versus 63 of 90 patients (70%) with single brain metastasis
(p  0.35). When examining the location of single brain
metastases (Table 6), we found that tumors in the cerebellum
and temporal lobes had a higher correlation with neurological
symptoms (odds ratio 3.7, p  0.046).
DISCUSSION
The brain is a frequent site of metastasis from NSCLC.
Although early detection of brain metastasis will alter surgi-
cal management and avoid unnecessary thoracotomy,4–9 pre-
operative screening of neurologically asymptomatic patients
has not been advocated. Many investigators consider the
incidence of occult brain metastasis to be quite low, partic-
ularly among patients with early disease,14–16 and view the
routine use of MRI and CT in asymptomatic patients as not
cost-effective.2,12,13,18
Toloza et al.22 pooled data from 17 studies and found a
13% average prevalence of brain metastasis by CT among
patients with NSCLC, but the prevalence rate ranged widely
from 0 to 32%. Advocates of preoperative screening for brain
metastases argue that studies demonstrating a low prevalence
are often skewed by a high proportion of patients with stage
1 disease, who are at lower risk of metastases.10 Contributing
to this controversy is the poorly understood pattern of
NSCLC spread. Although it is generally acknowledged that
metastases to the brain are more frequent with tumors staged
greater than T110,14–16 or the presence of nodal metasta-
TABLE 2. Histology and Distribution of Primary Lung Tumor in Symptomatic (Group 1) and Asymptomatic (Group 2)












Total 106 (58.6%) 18 (9.9%) 32 (17.7%) 9 (5%) 9 (5%) 7 (3.9%) 64 (35.4%) 103 (56.9%) 131 (72.4%) 42 (23.2%)
n  181
Group 1 71 (59.2%) 10 (8.3%) 22 (18.3%) 5 (4.2%) 8 (6.7%) 4 (3.3%) 40 (33.3%) 68 (56.7%) 75 (62.5%) 30 (25.0%)
n  120
Group 2 35 (57.4%) 8 (13.1%) 10 (16.4%) 4 (6.6%) 1 (1.6%) 3 (4.9%) 24 (39.3%) 35 (57.4%) 46 (75.4%) 12 (19.7%)
n  61
NSCLC, non–small cell lung carcinoma; NOF, not otherwise specified.
TABLE 3. T and N Stages of Symptomatic (Group 1) and Asymptomatic (Group 2) Patients with Brain Metastases
T1 T2 T3 T4 Unknown N0 N1 N2 N3 Nx
Total n  181 51 (28.2%) 70 (38.7%) 14 (7.7%) 9 (5%) 37 (20.4%) 60 (33.2%) 13 (7.2%) 57 (31.5%) 43 (23.7%) 8 (4.4%)
Group 1 n  120 38 (31.7%) 48 (40.0%) 8 (6.7%) 4 (3.3%) 22 (18.3%) 51 (42.5%) 9 (7.5%) 37 (30.8%) 21 (17.5%) 2 (1.7%)
Group 2 n  61 13 (21.3%) 22 (36.1%) 6 (9.8%) 5 (8.2%) 15 (24.6%) 9 (14.7%) 4 (6.6%) 20 (32.8%) 22 (36.1%) 6 (9.8%)
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sis,11,17 metastases have been reported to spread from even
small primary tumors in the absence of other metastases.3,4,6
To date, there has been no comprehensive study that evalu-
ates the factors associated with brain metastasis in asymp-
tomatic patients compared with those who are symptomatic.
Therefore, the purpose of this study was to determine whether
there are any specific tumor features, such as location, size,
stage at diagnosis, or tumor cell type, that could help to
distinguish which patients are likely to have asymptomatic
brain metastases.
In terms of primary tumor distribution on CT scan, we
found that most lung cancers in both the symptomatic and
asymptomatic groups occurred in the right upper lobe. Our
results are in keeping with previous studies that have shown
that most lung cancers occur in the upper lobes, with a typical
upper to lower lobe ratio of roughly 2.5:1.0.19,23 Therefore,
we could not conclude that a tumor’s lobar site of origin
correlated to any increased likelihood of brain metastases.
In terms of the evaluation of T stage, we found brain
metastases in patients with all T stages. Of note, 31.7% of
patients in group 1 and 21.3% of patients in group 2 had
tumors smaller than 3 cm (T1 stage). When we evaluated our
patient population based on N stage, patients with N0 disease
formed the largest group (33% of all patients). Although
group 2 (asymptomatic patients) had a higher N stage, we
speculate that this reflects an inclination of clinicians to
perform additional imaging examinations when there is evi-
dence of nodal spread. Taken together, a large proportion of
patients, both neurologically symptomatic and asymptomatic,
had early, local lung cancer. We did not have data regarding
the tumor staging of all NSCLC patients treated at our
institution during the study period to examine the likelihood
of brain metastasis based on tumor staging; thus, we can only
speculate as to the importance of this finding. The SEER data
show that 18.2% of patients had local disease, and 29% of
patients had regional disease at diagnosis.21 Because our
institution is a referral center for lung cancer, our patient base
may have more advanced disease than that reflected in na-
tional statistics. The high proportion of patients with T1 or
N0 disease in our study suggests a higher prevalence of brain
metastasis than previously thought. Our data also question the
current understanding that patients with local disease are
much less likely to have brain metastasis than those with
more advanced disease. Further research is needed to under-
stand NSCLC tumor behavior with regard to CNS spread.
There was no correlation between the number and
distribution of brain metastases and tumor histology. We also
found no significant difference in primary tumor histology
TABLE 4. Breakdown of Patients with Brain Metastases with and without Nodal Metastases Based on Cell Type of Primary
Tumor at Staging
Tumor Type N Patients without lymph node metastasis Patients with lymph node metastases
Adenocarcinoma 106 32 (30.2%) 74 (69.8)
Squamous cell 18 2 (11.1%) 16 (88.9%)
Large cell 32 17 (53.1) 15 (46.9%)
NSCLC NOF 9 1 (11.1%) 8 (88.9%)
Poorly differentiated 9 4 (44.4%) 5 (55.6%)
Unknown 7 4 (57.1%) 3 (42.9%)
NSCLC, non–small cell lung carcinoma; NOF, not otherwise specified.
TABLE 5. Correlation between Plurality of Brain Metastases in Symptomatic (Group 1) and Asymptomatic (Group 2) Patients
and Tumor Type
Total Adenocarcinoma Squamous Large cell NSCLC NOF Poorly differentiated Unknown
Multiple brain mets 91 (50.3%) 55 (30.4%) 12 (6.6%) 14 (7.7%) 5 (2.8%) 2 (1.1%) 3 (1.7%)
Group 1 57 (47.5%) 35 (29.2%) 12 (6.6%) 6 (5.0%) 2 (1.7%) 1 (0.8%) 1 (0.8%)
Group 2 34 (55.7%) 20 (32.8%) 2 (3.3%) 6 (9.8%) 3 (4.9%) 1 (1.6%) 2 (3.3%)
Single brain mets 90 (49.7%) 51 (28.2%) 6 (3.3%) 18 (9.9%) 4 (2.2%) 7 (3.9%) 4 (2.2%)
Group 1 63 (52.5%) 36 (30.0%) 10 (8.3%) 4 (3.3%) 3 (2.5%) 7 (5.8%) 3 (2.5%)
Group 2 27 (44.3%) 15 (24.6%) 8 (13.1%) 2 (3.3%) 1 (1.6%) 0 1 (1.6%)
Mets, Metastases; NSCLC, non–small cell lung carcinoma; NOF, not otherwise specified.
TABLE 6. Distribution of Single Brain Metastasis in
Symptomatic (Group 1) and Asymptomatic (Group 2)
Patients
Group 1 Group 2
Anatomic location n  120 n  61
Cerebellum/spine 16 4
Frontal lobe 17 12
Parietal lobe 6 7
Temporal lobe 9 0
Occipital lobe 4 2
Frontal/parietal lobe 3 0
Parietal/occipital lobe 4 1
Other 5 0
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between asymptomatic and symptomatic patients. There was
a significant increase in the occurrence of brain metastases in
patients with adenocarcinoma and large-cell carcinoma his-
tology. Our results are in accordance with a study by Salva-
tierra et al.,6 who reported that non-squamous cell lung cancer
histology was a risk factor for brain metastasis. We found that
squamous cell tumors less frequently spread to the CNS than
other histological subtypes, particularly in the absence of
lymph node metastases. On the contrary, large-cell tumors
spread to the CNS regardless of lymph node status. There-
fore, screening for brain metastasis may not be as cost-
effective in patients with localized squamous cell tumor,
whereas it will provide a higher yield in all patients initially
diagnosed with large-cell lung cancer.
A significant proportion of patients (19.2%) in our
study had isolated brain metastases and an absence of nodal
involvement. Studies have shown that those patients with
early stage lung disease in the thorax and an isolated brain
metastasis have better survival rates after resection of both
lesions.24–27 This fact, along with our results, suggests that
patients with resectable lung cancers, especially those with
local disease and adenocarcinoma or large-cell carcinoma
histology, should receive a staging neurological CT or MRI.
Among our patients with CNS metastases, 30.9% had no
other extrathoracic metastasis. Therefore, the absence of
distant metastases to the abdomen, pelvis, or skeleton should
not be used to preclude the absence of a brain metastasis.
There are several limitations of this study. Because of
its retrospective design, tumor, node, metastasis and histo-
logical distribution of the study population was not com-
pletely available. In addition, our patient group was largely
derived from a referral group to a lung cancer multidisci-
plinary oncology and surgical clinic. Consequently, the true
prevalence of brain metastasis of lung cancer could not be
assessed. In addition, both CT and/or MRI were used for
imaging the brain for metastases. Studies have shown that
MRI is more sensitive than CT in detecting brain lesions28,29;
therefore, the detection of brain metastasis at initial staging
may not be as accurate for patients who underwent CT alone.
Although surgical and clinical information was used to
modify tumor, node, metastasis staging whenever available,
staging information was largely derived from CT. The detec-
tion of hilar and mediastinal nodal disease by CT is insuffi-
ciently sensitive and specific,30 yet CT is the best method
available for patients who do not undergo surgical staging.
With the increased use of PET or combined PET-CT,31 more
information may become available in the future regarding the
relationship between nodal disease and brain metastasis.
CONCLUSION
In conclusion, no specific T or N staging features of
lung cancer on CT helped to distinguish which patients had
asymptomatic brain metastases on initial staging. We encoun-
tered a large number of patients with early disease (N0 and
T1) who had asymptomatic metastatic spread to the CNS.
This was more likely in patients with adenocarcinoma and
large-cell carcinoma. A large number of patients with brain
metastases had no other evidence of distant metastases. Our
results raise questions regarding the current practice recom-
mendation of limiting brain imaging to those patients with
neurological symptoms. Further research is recommended to
evaluate the use of CNS imaging for routine staging in all
patients with NSCLC.
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